Vol 10 Issue 2

Download PDF

Featuring

Issue Spotlight: Non-clinical/translational tools & technologies
Scalability 2024
Other articles
Webinars

Non-clinical/translational tools & technologies

Guest Editor:

Shon Green, Director, Clinical Translation at Adicet Bio

Foreword

The March 2024 issue of Cell & Gene Therapy Insights

Shon Green

1 April

Read

Expert Insight

Preclinical trends in developing genetically altered cell therapies

Mary Ellen Cosenza

25 March

Read

Viewpoint

Regulatory and scientific considerations for building translational cell and gene therapy packages

Shannon Dahl

23 February

Read

Interview

The preclinical journey: transitioning a novel cell therapy into early phase clinical trials

Silvio Manfredo-Vieira

6 March

Read

Evolution in the landscape of non-clinical safety testing for advanced therapies

Michaela Sharpe

19 January

Read

Scalability 2024

Innovator Insight

Advancing gene therapy development with a multi-serotype AAV affinity resin

Nicolas Laroudie, Quentin Bazot

3 April

Read

FastFacts

Transient and suspension: scalable yet flexible single-use process for multiple AAV serotypes

Johanna Viiliäinen

19 March

Read

Interview

Advancing AAV production scalability: enhancing purity, productivity, and yield

Ashish Saksule

19 March

Read

Journal articles

FastFacts

Dissolvable microcarriers: a modular, high-yield solution for seed train through production

Tom Bongiorno

14 March

Read

Webinar Digest

What goes into developing an in-house method for quantitation of residual host cell DNA?

Ilaria Scarfone

12 March

Read

Poster

5 dos and don'ts for regulatory compliance in AAV manufacturing

3 April

Read

5 best practices for lentiviral purification and downstream processing success

3 April

Read

Interview

Gene therapy is having a monumental year: how can the industry keep up with supply?

Suman Subramanian

3 April

Read

Quantitative viral vector characterization: prioritizing genome vector integrity

David Dobnik

21 February

Read

Closing the gap: Modelling benefits of AAV scale-up using novel enhancers

J Diallo, J De Jong, A Vervoort

25 January

Watch

Trends in innovation for downstream process intensification, product yield, single-use closed systems, and gentle ATMP bioprocessing: a KOL panel discussing 2024 insights in gene therapy manufacturing

Rachel Legmann, Andrew Tustian

27 February

Watch

Achieving consistency in fill and finish for cell therapies

Min Sung Park, Meredith Safford

28 February

Watch

Accelerating AAV process development with PAT-driven TFF system

Teva Smith

6 March

Watch

Positioning early cell therapy programs for clinical success: insights to mitigate risk and ensure GMP readiness

K Watanabe, M Sadik, M Duggan

7 March

Watch

CELL AND GENE THERAPY INSIGHTS

March 2024 Issue

Vol 10 Issue 2

Featuring

SPOTLIGHT

Non-clinical/translational tools & technologies

Foreword

The March 2024 issue of Cell & Gene Therapy Insights

Expert Insight

Preclinical trends in developing genetically altered cell therapies

Viewpoint

Regulatory and scientific considerations for building translational cell and gene therapy packages

Interview

The preclinical journey: transitioning a novel cell therapy into early phase clinical trials

Evolution in the landscape of non-clinical safety testing for advanced therapies

Vectors FOCUS

Scalability 2024

Innovator Insight

Advancing gene therapy development with a multi-serotype AAV affinity resin

FastFacts

Transient and suspension: scalable yet flexible single-use process for multiple AAV serotypes

Interview

Advancing AAV production scalability: enhancing purity, productivity, and yield

Journal articles

FastFacts

Dissolvable microcarriers: a modular, high-yield solution for seed train through production

Webinar Digest

What goes into developing an in-house method for quantitation of residual host cell DNA?

Poster

5 dos and don'ts for regulatory compliance in AAV manufacturing

5 best practices for lentiviral purification and downstream processing success

Interview

Gene therapy is having a monumental year: how can the industry keep up with supply?

Quantitative viral vector characterization: prioritizing genome vector integrity

Webinars

Closing the gap: Modelling benefits of AAV scale-up using novel enhancers

Trends in innovation for downstream process intensification, product yield, single-use closed systems, and gentle ATMP bioprocessing: a KOL panel discussing 2024 insights in gene therapy manufacturing

Achieving consistency in fill and finish for cell therapies

Accelerating AAV process development with PAT-driven TFF system

Positioning early cell therapy programs for clinical success: insights to mitigate risk and ensure GMP readiness

CELL AND GENE THERAPY INSIGHTS

March 2024 Issue

Vol 10 Issue 2

Featuring

SPOTLIGHT

Non-clinical/translational tools & technologies

Foreword

The March 2024 issue of Cell & Gene Therapy Insights

Expert Insight

Preclinical trends in developing genetically altered cell therapies

Viewpoint

Regulatory and scientific considerations for building translational cell and gene therapy packages

Interview

The preclinical journey: transitioning a novel cell therapy into early phase clinical trials

Evolution in the landscape of non-clinical safety testing for advanced therapies

Vectors FOCUS

Scalability 2024

Innovator Insight

Advancing gene therapy development with a multi-serotype AAV affinity resin

FastFacts

Transient and suspension: scalable yet flexible single-use process for multiple AAV serotypes

Interview

Advancing AAV production scalability: enhancing purity, productivity, and yield

Journal articles

FastFacts

Dissolvable microcarriers: a modular, high-yield solution for seed train through production

Webinar Digest

What goes into developing an in-house method for quantitation of residual host cell DNA?

Poster

5 dos and don'ts for regulatory compliance in AAV manufacturing

5 best practices for lentiviral purification and downstream processing success

Interview

Gene therapy is having a monumental year: how can the industry keep up with supply?

Quantitative viral vector characterization: prioritizing genome vector integrity

Webinars

Closing the gap: Modelling benefits of AAV scale-up using novel enhancers

﻿Trends in innovation for downstream process intensification, product yield, single-use closed systems, and gentle ATMP bioprocessing: a KOL panel discussing 2024 insights in gene therapy manufacturing

Achieving consistency in fill and finish for cell therapies

Accelerating AAV process development with PAT-driven TFF system

﻿Positioning early cell therapy programs for clinical success: insights to mitigate risk and ensure GMP readiness

Trends in innovation for downstream process intensification, product yield, single-use closed systems, and gentle ATMP bioprocessing: a KOL panel discussing 2024 insights in gene therapy manufacturing

Positioning early cell therapy programs for clinical success: insights to mitigate risk and ensure GMP readiness